IDYA•benzinga•
Looking Into IDEAYA Biosciences's Return On Capital Employed
Summary
Benzinga Pro data, IDEAYA Biosciences (NASDAQ:IDYA) reported Q2 sales of $5.85 million. Earnings fell to a loss of $22.06 million, resulting in a 57.4% decrease from last quarter.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga